Today: 3 June 2026
Valaris stock price dips in premarket after Transocean deal-fueled 34% jump
10 February 2026
1 min read

Valaris stock price dips in premarket after Transocean deal-fueled 34% jump

New York, Feb 10, 2026, 05:24 EST — Premarket

Valaris Limited shares slipped in premarket trading Tuesday, following a big surge the previous session after Transocean said it would acquire the offshore driller through an all-stock transaction.

Valaris shares slipped around 2% to $82.18, following a 34.3% surge on Monday that took the stock to a close of $83.82.

This is suddenly important, since the offer comes in shares, not in cash. Stock-for-stock deals like this one usually mean the target’s price will track the buyer’s shares, as traders work through the numbers on the exchange ratio.

The “spread” is also in focus. That’s the difference between Valaris’ market price and what Transocean’s stock suggests it should be. When the gap widens, it signals the market is demanding more to account for time, volatility, and risks tied to the deal.

Transocean is set to hand over 15.235 of its own shares for every Valaris share, putting Valaris’ value at $82.12 per share—a 31.6% premium over its last close, according to Reuters calculations. The deal, pending both shareholder and regulatory sign-off, is slated to wrap up in the second half of 2026.

Transocean CEO Keelan Adamson described the deal as “well-timed” for the offshore drilling upcycle, pointing to “more than $200 million” in identified cost synergies. Valaris boss Anton Dibowitz highlighted how the merger brings together Transocean’s deepwater assets with Valaris’ jackup rigs, saying the combined group would be “capable of operating any rig at any water depth.”

According to a Valaris filing, the transaction takes the form of a court-approved scheme of arrangement governed by Bermuda law. The companies also intend to submit joint proxy materials to the SEC before putting the deal to a shareholder vote.

Transocean closed out Monday with a 5.9% gain at $5.71, only to dip after hours—a move that pushed on Valaris shares early Tuesday. Since the exchange ratio is locked in, Valaris’ implied value now tracks wherever Transocean’s stock heads.

Even so, there’s a clear risk. If approvals drag on, Transocean shares slide, or customers and regulators balk, the spread could widen—with Valaris taking the hit, deal or no deal.

Investors, for the moment, are shrugging off the initial surge and zeroing in on what’s next. Valaris is set to report its fourth-quarter 2025 numbers before the NYSE bell on Feb. 19, followed by a 10 a.m. ET conference call.

Latest articles

Archer Aviation trades under $7 as next test looms for air-taxi gamble

Archer Aviation trades under $7 as next test looms for air-taxi gamble

3 June 2026
Archer Aviation shares dipped below $7 premarket after closing at $6.74, as investors weigh heavy cash burn—$217.7 million Q1 net loss, $1.78 billion cash on hand—against hopes for first U.S. eVTOL flights this year; Cantor Fitzgerald cut its price target to $11 but kept an Overweight rating, while 46 disclosed risks and ongoing certification challenges cloud near-term outlook.
Broadcom’s $280 Billion AI Rally Hits Key Test

Broadcom’s $280 Billion AI Rally Hits Key Test

3 June 2026
Broadcom’s stock soared 14% in four days, adding $280 billion in value ahead of Wednesday’s earnings after Alphabet’s $80 billion equity raise spotlighted AI data-center suppliers; with options implying a 9% share move either way, investors await proof that surging AI demand is translating into real revenue growth.
J-Star Stock Moves Up After Texas Battery Update in Pre-Market

J-Star Stock Moves Up After Texas Battery Update in Pre-Market

3 June 2026
J-Star Holding Co. surged to $1.36 in premarket trading after new disclosures on its proposed $122.5 million Baytown, Texas solid-state battery plant, pushing shares above Nasdaq’s $1 minimum less than a week before a key shareholder vote on a reverse split aimed at regaining compliance.
Legend Biotech jumps 42% as traders look at results from small cancer study

Legend Biotech jumps 42% as traders look at results from small cancer study

3 June 2026
Legend Biotech shares soared 42% to $36.28 after early Phase 1 data showed all six higher-dose patients with relapsed or refractory B-cell non-Hodgkin lymphoma responded to its in vivo CAR-T therapy LB2501, with five complete responses; UBS raised its price target to $49, citing the therapy’s outlook, but the results are early and based on a small group with short follow-up.
T1 Energy Stock Falls Premarket After $32M KORE Battery Deal

T1 Energy Stock Falls Premarket After $32M KORE Battery Deal

3 June 2026
T1 Energy shares fell 1.3% premarket after announcing a $32 million KORE Power acquisition to expand into battery storage and AI data-center infrastructure, just a day after a 15.7% stock surge; Northland initiated coverage with an outperform rating and $16 target, but flagged deal execution and funding as key risks.
monday.com stock price: MNDY holds near $78 after guidance reset, 2027 targets shelved
Previous Story

monday.com stock price: MNDY holds near $78 after guidance reset, 2027 targets shelved

Eddie Bauer bankruptcy: liquidation sales begin as 180-store operator seeks buyer
Next Story

Eddie Bauer bankruptcy: liquidation sales begin as 180-store operator seeks buyer

Go toTop